HIV-1 co-receptor usage of patients experienced anti-retroviral therapy / 中华预防医学杂志
Chinese Journal of Preventive Medicine
; (12): 985-988, 2010.
Article
de Zh
| WPRIM
| ID: wpr-349902
Bibliothèque responsable:
WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To investigate HIV-1 co-receptor usage in patients experienced anti-retroviral therapy (ART) in Anhui and Henan province of China.</p><p><b>METHODS</b>A total of 45 HIV-1 infected individuals who have experienced ART and 109 un-experienced ART patients from Anhui and Henan province, which were called as treatment group and treatment-negative group, were selected as study subjects. HIV-1 strains were isolated from peripheral blood mononuclear cells of whole blood from patients. HIV-1 p24 in the culture supernatant was measured using a commercial enzyme-linked immunosorbent assay (ELISA) kit. HIV-1 co-receptor usage was identified using Ghost cell lines expressing CD4 and the chemokine receptor CCR5 or CXCR4.</p><p><b>RESULTS</b>Among 45 HIV strains from the treatment group, 22 (48.9%) strains used CCR5 as a co-receptor (R5 tropic strain), 21 (46.7%) strains used CXCR4/CCR5 as a co-receptor (X4/R5 duel tropic strain), and 2 (4.4%) used only CXCR4 as a co-receptor (X4 tropic strain). In 109 strains from treatment-negative group, 96 (88.1%) strains used CCR5 as a co-receptor (R5 tropic strain), 13 (11.9%) strains used CCR5/CXCR4 as a co-receptor use (X4/R5 strain). A significant difference was found between two groups in X4 co-receptor usages (χ(2) = 27.30, P < 0.05). Furthermore, after treated with AZT + DDI + NVP, the HIV-1 CXC4/CCR5 utilization was 59.09% (13/22), meanwhile after treated with D4T + DDI + NVP, the HIV-1 CXC4/CCR5 utilization was 43.48% (10/23), which the difference was not statistical significant (χ(2) = 1.10, P = 0.30).</p><p><b>CONCLUSION</b>HIV-1 CXCR4/CCR5 co-receptor utilization was higher in ART patients than treatment-negative patients.</p>
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Antiviraux
/
Récepteur VIH
/
Cellules cultivées
/
Syndrome d'immunodéficience acquise
/
VIH-1 (Virus de l'Immunodéficience Humaine de type 1)
/
Récepteurs CCR5
/
Récepteurs CXCR4
/
Utilisations thérapeutiques
/
Traitement médicamenteux
/
Métabolisme
Limites du sujet:
Adult
/
Aged
/
Female
/
Humans
/
Male
langue:
Zh
Texte intégral:
Chinese Journal of Preventive Medicine
Année:
2010
Type:
Article